Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.

MLA

Eisman, John A., et al. “Fracture Risk in Women with Osteoporosis Initiated on Gastro-Resistant Risedronate versus Immediate Release Risedronate or Alendronate: A Claims Data Analysis in the USA.” Osteoporosis International : A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, vol. 34, no. 5, May 2023, pp. 977–91. EBSCOhost, https://doi.org/10.1007/s00198-022-06627-0.

APA

Eisman, J. A., Cortet, B., Boolell, M., Ionescu-Ittu, R., Vekeman, F., Heroux, J., & Thomasius, F. (2023). Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA. Osteoporosis International : A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 34(5), 977–991. https://doi.org/10.1007/s00198-022-06627-0

Chicago

Eisman, John A, Bernard Cortet, Mitra Boolell, Raluca Ionescu-Ittu, Francis Vekeman, Julie Heroux, and Friederike Thomasius. 2023. “Fracture Risk in Women with Osteoporosis Initiated on Gastro-Resistant Risedronate versus Immediate Release Risedronate or Alendronate: A Claims Data Analysis in the USA.” Osteoporosis International : A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 34 (5): 977–91. doi:10.1007/s00198-022-06627-0.